New pill shows promise for tough blood cancers in early trial
Disease control
Completed
This early-phase study tested an experimental oral drug called LP-108, given alone or with another drug (azacitidine), in 32 adults with certain blood cancers (MDS, CMML, or AML) that had returned or stopped responding to prior therapy. The main goals were to find the safest dose…
Phase: PHASE1 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC